Released on: April 28, 2008, 8:47 am

Press Release Author: AnaSpec Inc.

Industry: Biotech

Press Release Summary: AnaSpec has introduced a full suite of phospho-specific
ErbB-2 (Her-2) polyclonal antibodies.

Press Release Body: San Jose, CA - April 28, 2008

With experience in the synthesis of phospho-specific peptides, AnaSpec has
introduced a full suite of phospho-specific ErbB-2 (Her-2) polyclonal antibodies.
These phosphorylated antibodies show no cross reactivity and are specific for
phospho-tyrosine at position 877, 1112, 1222 and 1248.

The HER-2/neu, also known as c-erbB2, or CD340 proto-oncogene encodes a 185-kDa
transmembrane receptor protein. It has partial homology with the epidermal growth
factor receptor and shares intrinsic tyrosine kinase activity with that receptor.
HER2 plays a role in oncogenesis in breast, ovarian, gastric, and lung carcinoma and
endocrine tumors.

HER2 is constitutively activated in the absence of ligand and signaling occurs
through phosphorylation of specific tyrosine residues which serve as docking sites
for the adaptor molecules SHC and GRB2 with subsequent activation of Ras-ERK and
PI-3K pathways. HER2 activation of the extracellular signal-regulated kinase (ERK)
pathway is primarily dependent on phosphorylation of Y1248/1253 of HER2 and mutation
of this residue substantially diminishes the transforming potential of HER2. Other
important phosphorylation sites of HER-2 include Y877 and Y1112. AnaSpec offers
several anti-Her-2/neu (c-erbB2) antibodies developed against the phosphorylated
tyrosine-containing Her-2/neu sequences, and corresponding antibodies raised to the
same sequence but surrounding non-phosphorylated tyrosine.

Listing of Her-2 Antibodies:
Anti - ErbB-2 (Her-2)
Anti - ErbB-2 (Her-2) (pTyr877)
Anti - ErbB-2 (Her-2) (paired 877)
Anti - ErbB-2 (Her-2) (pTyr1112)
Anti - ErbB-2 (Her-2) (paired 1112)
Anti - ErbB-2 (Her-2) (pTyr1222)
Anti - ErbB-2 (Her-2) (paired1222)
Anti - ErbB-2 (Her-2) (pTyr1248)
Anti - ErbB-2 (Her-2) (paired1248)

REFERENCES:
Coussens L. et al. Science 230,1132 (1985).
Cobleigh, M. et al J. Clin. Oncol. 17, 2639 (1999).
Castilla-Guerra L. et al. Histopathology 31, 144 (1997).
Yonemura, Y. et al. Cancer 67, 2914 (1991).

Company Info
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to
pharmaceutical, biotech, and academic research institutions throughout the world.
With a vision for innovation through synergy, AnaSpec focuses on three core
technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and
combinatorial chemistry.
For more information, visit www.anaspec.com


Web Site: http://www.anaspec.com

Contact Details: AnaSpec Inc.
2149 O\'Toole Ave.
San Jose, CA 95131
1-408-452-5055 (Tel)
1-408-452-5059 (Fax)
1-800-452-5530
ping@anaspec.com
www.anaspec.com